Department of Biochemistry and Molecular Biology, Biological Models Laboratory, University of the Philippines Manila, Ermita, Manila, Philippines.
J Med Virol. 2021 Mar;93(3):1702-1721. doi: 10.1002/jmv.26548. Epub 2020 Oct 8.
The ongoing pandemic caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), affects thousands of people every day worldwide. Hence, drugs and vaccines effective against all variants of SARS-CoV-2 are crucial today. Viral genome mutations exist commonly which may impact the encoded proteins, possibly resulting to varied effectivity of detection tools and disease treatment. Thus, this study surveyed the SARS-CoV-2 genome and proteome and evaluated its mutation characteristics. Phylogenetic analyses of SARS-CoV-2 genes and proteins show three major clades and one minor clade (P6810S; ORF1ab). The overall frequency and densities of mutations in the genes and proteins of SARS-CoV-2 were observed. Nucleocapsid exhibited the highest mutation density among the structural proteins while the spike D614G was the most common, occurring mostly in genomes outside China and United States. ORF8 protein had the highest mutation density across all geographical areas. Moreover, mutation hotspots neighboring and at the catalytic site of RNA-dependent RNA polymerase were found that might challenge the binding and effectivity of remdesivir. Mutation coldspots may present as conserved diagnostic and therapeutic targets were found in ORF7b, ORF9b, and ORF14. These findings suggest that the virion's genotype and phenotype in a specific population should be considered in developing diagnostic tools and treatment options.
由新型冠状病毒(SARS-CoV-2)引起的持续大流行每天在全球影响着成千上万的人。因此,今天针对所有 SARS-CoV-2 变体有效的药物和疫苗至关重要。病毒基因组经常发生突变,这可能会影响编码蛋白,可能导致检测工具和疾病治疗的有效性发生变化。因此,本研究调查了 SARS-CoV-2 的基因组和蛋白质组,并评估了其突变特征。SARS-CoV-2 基因和蛋白质的系统发育分析显示出三个主要分支和一个小分支(P6810S;ORF1ab)。观察到 SARS-CoV-2 基因和蛋白质中的总体突变频率和密度。在结构蛋白中,核衣壳表现出最高的突变密度,而刺突 D614G 是最常见的,主要发生在中国和美国以外的基因组中。ORF8 蛋白在所有地理区域的突变密度最高。此外,还发现了 RNA 依赖性 RNA 聚合酶的临近和催化部位的突变热点,这可能会挑战瑞德西韦的结合和有效性。在 ORF7b、ORF9b 和 ORF14 中发现了突变冷点,这些冷点可能是保守的诊断和治疗靶点。这些发现表明,在开发诊断工具和治疗方案时,应考虑特定人群中病毒粒子的基因型和表型。